세계의 임상시험 서비스 시장 : 유형별, 단계별, 치료법별, 모달리티별, 딜리버리 모델별 - 예측(-2030년)

The global clinical trial services market is projected to reach USD 101.86 billion in 2030 from USD 66.59 billion in 2025, growing at a CAGR of 8.9% during the forecast period. This market is expanding as pharmaceutical, biotechnology, and medical device companies are increasingly outsourcing their clinical research activities to Contract Research Organizations (CROs). Flexible service models, such as Functional Service Provider (FSP) and hybrid service delivery models, offered by CROs enable cost management while allowing companies to retain control over critical operations. There is a growing demand for patient-centric trials, leveraging decentralized models, wearable devices, and digital platforms to enhance patient participation and retention. Technological advancements, including artificial intelligence (AI) and real-world data (RWD), are optimizing trial efficiency, site selection, and patient recruitment. The rising demand for personalized and precision medicine is driving an increase in clinical studies focused on targeted therapies, requiring CROs to support complex trial designs. Regulatory bodies are emphasizing pediatric clinical trials, requiring CROs to develop specialized expertise. Additionally, FDA guidelines promoting diversity in clinical trials are creating opportunities for CROs to expand patient recruitment and ensure broader representation. The increasing pipeline of new drug modalities, including cell and gene therapies, biologics, and RNA-based treatments, is further driving the need for specialized clinical research services.

"The oncology therapy area segment held the largest share in the clinical trial services market, by therapy area, during the forecast period"

In 2024, the oncology therapy area held the largest market within the clinical trial services market by therapy area. Factors such as the large number of cancer cases worldwide and the need for new treatments are supporting the large share of this therapy area. Cancer research is complex, requiring trials for targeted therapies, immunotherapies, and combination treatments. Regulatory agencies prioritize cancer drug approvals, leading to more trials in this area. Advances in precision medicine and biomarker research have also increased oncology trials, requiring expertise in patient recruitment and trial management. Strong investments from pharmaceutical companies, government agencies, and patient organizations further drive cancer research, making oncology the leading segment in clinical trials.

"The pharmaceutical & biopharmaceutical companies end user segment held the largest market share in the clinical trials services market, by end user, during the forecast period"

Pharmaceutical and biopharmaceutical companies dominated the clinical trial services end-user/sponsor market during the forecast period. Conducting in-house trials demands substantial investments in infrastructure, personnel, and regulatory compliance, making outsourcing a more cost-effective and efficient alternative as trial complexity increases. Partnering with Contract Research Organizations (CROs) allows these companies to leverage expertise in trial design, patient recruitment, regulatory adherence, and data management, expediting drug development. Additionally, the expanding R&D pipeline and growing focus on precision medicine have led pharmaceutical companies to outsource clinical services and laboratory testing, minimizing operational burdens and optimizing resources.

"Asia Pacific: The fastest growing region in the clinical trial services market"

The Asia Pacific clinical trial services market is projected to register the highest growth rate during the forecast period. This high growth is attributed to its large patient pool, high incidence of chronic and infectious diseases, and growing focus on developing biologics, biosimilars, and advanced therapies. Global pharmaceutical companies are increasingly shifting manufacturing and clinical research to the region to benefit from cost advantages, regulatory improvements, and better patient retention in trials. Additionally, government support and increasing investments in clinical research have further driven the outsourcing of clinical trial activities to APAC, contributing to its strong market growth.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 - 44%, Tier 2 - 32%, and Tier 3 - 24%
• By Designation: (Managers) - 45%, (CXOs, Directors)- 30%, and(Executives) - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, ROW -15%

List of Companies Profiled in the Report:

• IQVIA Inc. (US)
• Thermo Fisher Scientific Inc. (US)
• Fortrea (US)
• ICON Plc (Ireland)
• Syneos Health (US)
• Laboratory Corporation of America Holdings (US)
• Medpace (US)
• Wuxi AppTec (China)
• Frontage Labs (US)
• Pharmaron (US)
• Tigermed (China)
• SGS Societe Generale De Surveillance SA. (Switzerland)
• Eurofins Scientific (Luxembourg)
• Linical (Japan)
• Parexel International Corporation (US)
• Worldwide Clinical Trials (US)
• Novotech (Australia)
• PSI (Switzerland)
• Allucent (US)
• Premier Research (US)
• Clario (US)
• KCR S.A. (US)
• Rho, Inc. (US)
• Advanced Clinical (US)

Research Coverage:

This report provides a detailed picture of the global clinical trial service market. It aims to estimate the size and future growth potential of the market across different segments such as the service type, therapy area, phase, delivery model, modality, end user/sponsor, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the clinical trial services market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; partnerships, agreements, new service launches, mergers and acquisitions, and recent developments associated with the clinical trial services market. Competitive analysis of upcoming startups in the clinical trial services market ecosystem is covered in this report.

Reasons to buy this report :

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall clinical trial services market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (Increasing focus on patient-centric trials (DCTs), increasing clinical trials for precision/personalized medicines supporting growth in clinical trial outsourcing, rising R&D investments and patent cliff pressure driving growth in outsourcing clinical trial activities, service flexibility offered by CROs for clinical development (FSP, FSO, Hybrid) and technological integrations), opportunities (Increased focus on pediatric clinical trials, regulatory requirement for increasing diversity in clinical trials, growing role of real-world evidence in drug approvals, expanding drug modalities (such as CGT, ADCs, Bispecific Abs) in clinical trials), and challenges (Cybersecurity or intellectual property concerns, and challenge of patient retention) influencing the growth of the clinical trial services market.
• Service Development/Innovation: Detailed insights on upcoming technologies, and new service launches in the clinical trial services market
• Market Development: Comprehensive information about lucrative markets - the report analyses the clinical trial services market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the clinical trial services market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players in the clinical trial services market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 REGIONAL SCOPE
  • 1.3.3 INCLUSIONS AND EXCLUSIONS
  • 1.3.4 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 GLOBAL MARKET ESTIMATION
  • 2.2.1 MARKET ESTIMATION METHODOLOGY
    • 2.2.1.1 Insights from primary experts
  • 2.2.2 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
• 2.3 MARKET GROWTH RATE PROJECTION
• 2.4 DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN CLINICAL TRIAL SERVICES MARKET
• 4.2 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY AND COUNTRY (2024)
• 4.3 CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE (2025 VS. 2030)
• 4.4 CLINICAL TRIAL SERVICES MARKET, BY END USER (2024)
• 4.5 CLINICAL TRIAL SERVICES MARKET, BY COUNTRY

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing focus on patient-centric trials (DCTs)
    • 5.2.1.2 Increasing clinical trials for precision/personalized medicines supporting growth in clinical trial outsourcing
    • 5.2.1.3 Rising R&D investments and patent cliff pressure driving growth in outsourcing clinical trial activities
    • 5.2.1.4 Service flexibility offered by CROs for clinical development (FSP, FSO, Hybrid)
    • 5.2.1.5 Technological integrations
  • 5.2.2 OPPORTUNITIES
    • 5.2.2.1 Increased focus on pediatric clinical trials
    • 5.2.2.2 Increasing regulatory requirements for increasing diversity in clinical trials
    • 5.2.2.3 Growing role of real-world evidence in drug approvals
    • 5.2.2.4 Expanding drug modalities (such as CGT, Tissue Engineering, Bispecific Abs) in clinical trials
  • 5.2.3 CHALLENGES
    • 5.2.3.1 Cybersecurity or intellectual property concerns
    • 5.2.3.2 Challenge of patient retention
    • 5.2.3.3 Growing market competition
• 5.3 MARKET TRENDS
  • 5.3.1 IN SILICO CLINICAL TRIALS
• 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.5 PRICING ANALYSIS
  • 5.5.1 PRICING ANALYSIS, BY KEY PLAYER (QUALITATIVE)
  • 5.5.2 INDICATIVE PRICING ANALYSIS, BY PHASE, 2024
  • 5.5.3 INDICATIVE PRICING ANALYSIS, BY THERAPEUTIC AREA, 2024
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Clinical trial management system (CTMS)
    • 5.9.1.2 Electronic data capture (EDC) systems
    • 5.9.1.3 Randomization and trial supply management (RTSM)
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Telemedicine and wearable devices
    • 5.9.2.2 AI and ML integration
• 5.10 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.11 REGULATORY LANDSCAPE
  • 5.11.1 REGULATORY FRAMEWORK
    • 5.11.1.1 North America
    • 5.11.1.2 Europe
    • 5.11.1.3 Asia Pacific
    • 5.11.1.4 RoW
  • 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.12 PORTER'S FIVE FORCES ANALYSIS
  • 5.12.1 THREAT OF NEW ENTRANTS
  • 5.12.2 THREAT OF SUBSTITUTES
  • 5.12.3 BARGAINING POWER OF SUPPLIERS
  • 5.12.4 BARGAINING POWER OF BUYERS
  • 5.12.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.13.2 BUYING CRITERIA
• 5.14 IMPACT OF AI/GEN AI ON CLINICAL TRIAL SERVICES MARKET
  • 5.14.1 INTRODUCTION
  • 5.14.2 MARKET POTENTIAL FOR CLINICAL TRIALS
  • 5.14.3 AI USE CASES
  • 5.14.4 KEY COMPANIES IMPLEMENTING AI
  • 5.14.5 FUTURE OF GENERATIVE AI IN CLINICAL TRIAL ECOSYSTEM

6 CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE

• 6.1 INTRODUCTION
• 6.2 CLINICAL TRIAL MANAGEMENT & MONITORING
  • 6.2.1 RISING ADOPTION OF ADVANCED TECHNOLOGIES SUCH AS ARTIFICIAL INTELLIGENCE AND RISE OF REMOTE CLINICAL MONITORING TO SUPPORT MARKET GROWTH
• 6.3 LABORATORY SERVICES
  • 6.3.1 ANALYTICAL TESTING SERVICES
    • 6.3.1.1 Increasing demand for analytical testing for drug development to drive market
  • 6.3.2 BIOANALYTICAL TESTING SERVICES
    • 6.3.2.1 Rising focus on biologics in advanced therapies to drive market
• 6.4 CLINICAL TRIAL DATA MANAGEMENT SERVICES
  • 6.4.1 BIOSTATISTICS
    • 6.4.1.1 Integration of real-world data (RWD) into statistical analysis to support market growth
  • 6.4.2 OTHER DATA MANAGEMENT SERVICES
• 6.5 CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES
  • 6.5.1 COMPLEXITIES ASSOCIATED WITH SUPPLY AND LOGISTICS TO DRIVE MARKET
• 6.6 CONSULTING
  • 6.6.1 INCREASING COMPLEXITIES DURING TRIALS TO DRIVE MARKET
• 6.7 PATIENT RECRUITMENT & RETENTION
  • 6.7.1 INCREASING REQUIREMENT FOR DECENTRALIZED CLINICAL TRIAL SERVICES TO BOOST MARKET GROWTH
• 6.8 MEDICAL WRITING
  • 6.8.1 INCREASED OUTSOURCING OF MEDICAL WRITING SERVICES IN EMERGING ECONOMIES TO DRIVE MARKET
• 6.9 SAFETY & PHARMACOVIGILANCE
  • 6.9.1 REGULATORY AND SAFETY MONITORING EXPERTISE OFFERED BY CROS TO SUPPORT MARKET GROWTH
• 6.10 OTHER SERVICE TYPES

7 CLINICAL TRIAL SERVICES MARKET, BY PHASE

• 7.1 INTRODUCTION
• 7.2 PHASE III
  • 7.2.1 HIGH SIGNIFICANCE OF PHASE III TRIALS TO DRIVE DEMAND FOR OUTSOURCING
• 7.3 PHASE II
  • 7.3.1 LONG DURATION OF PHASE II STUDIES TO CREATE GROWTH OPPORTUNITIES FOR CROS
• 7.4 PHASE I
  • 7.4.1 DECLINING TRIALS TO POSE CHALLENGE IN MARKET GROWTH
• 7.5 PHASE IV
  • 7.5.1 SIGNIFICANCE OF PHASE IV FROM REGULATORY VIEWPOINT TO SUPPORT MARKET GROWTH

8 CLINICAL TRIAL SERVICES MARKET, BY MODALITY

• 8.1 INTRODUCTION
• 8.2 SMALL MOLECULES
  • 8.2.1 EXTENSIVE PIPELINE OF DRUGS IN DEVELOPMENT PHASE AND GROWING INVESTMENTS IN R&D OF SMALL MOLECULES TO BOOST MARKET GROWTH
• 8.3 BIOLOGICS
  • 8.3.1 GROWING COLLABORATIONS TO DEVELOP NEW BIOLOGICS AND RISING REGULATORY SUPPORT TO PROPEL DEMAND
• 8.4 MEDICAL DEVICES & IVD
  • 8.4.1 SPECIALIZED SERVICES OFFERED BY CROS TO DRIVE DEMAND

9 CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA

• 9.1 INTRODUCTION
• 9.2 ONCOLOGY
  • 9.2.1 GROWING DISEASE BURDEN AND FOCUS ON DEVELOPING NOVEL MEDICINES FOR CANCER TO DRIVE MARKET
• 9.3 NEUROLOGY
  • 9.3.1 INCREASING R&D INVESTMENTS RELATED TO NEUROLOGICAL DISORDERS TO DRIVE MARKET
• 9.4 RESPIRATORY DISORDERS
  • 9.4.1 RISING INCIDENCE OF RESPIRATORY DISORDERS TO SUPPORT MARKET GROWTH
• 9.5 METABOLIC DISORDERS/ENDOCRINOLOGY
  • 9.5.1 INCREASING GLOBAL DIABETES POPULATION TO BOOST MARKET GROWTH
• 9.6 CARDIOVASCULAR SYSTEM DISORDERS
  • 9.6.1 HIGH FOCUS ON PHARMACEUTICAL R&D ATTRIBUTED TO RISING MORTALITY RATES DUE TO CVD TO DRIVE MARKET
• 9.7 DERMATOLOGY
  • 9.7.1 GROWING FOCUS ON DRUG DEVELOPMENT FOR VARIOUS SKIN CONDITIONS TO SUPPORT MARKET GROWTH
• 9.8 GASTROINTESTINAL DISEASES
  • 9.8.1 EXPANSION AND DEVELOPMENT OF GASTROINTESTINAL DRUG PRODUCT LINE TO PROPEL MARKET
• 9.9 IMMUNOLOGICAL DISORDERS
  • 9.9.1 GROWING CLINICAL RESEARCH FOR IMMUNOLOGICAL DISORDERS TO FUEL MARKET GROWTH
• 9.10 INFECTIOUS DISEASES
  • 9.10.1 RISING OUTBREAKS OF INFECTIOUS DISEASES TO INCREASE DRUG DISCOVERY ACTIVITIES AND DRIVE MARKET
• 9.11 PSYCHIATRY
  • 9.11.1 GROWING INCIDENCE OF PSYCHIATRIC DISORDERS TO SUPPORT MARKET GROWTH
• 9.12 OPHTHALMOLOGY
  • 9.12.1 RISING NUMBER OF OPHTHALMOLOGY PIPELINE DRUGS TO SUPPORT SEGMENT GROWTH
• 9.13 HEMATOLOGY
  • 9.13.1 CONSISTENT DRUG DEVELOPMENT EFFORTS FOR HEMATOLOGICAL DISORDERS TO SUPPORT MARKET GROWTH
• 9.14 GENITOURINARY & WOMEN'S HEALTH
  • 9.14.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO PROPEL MARKET
• 9.15 OTHER THERAPEUTIC AREAS

10 CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL

• 10.1 INTRODUCTION
• 10.2 FULL-SERVICE OUTSOURCING (FSO) MODEL
  • 10.2.1 RISE IN NUMBER OF EMERGING BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET
• 10.3 FUNCTIONAL SERVICE PROVIDER (FSP) MODEL
  • 10.3.1 GROWING ADOPTION OF FSP SERVICE BY LARGE PHARMACEUTICAL COMPANIES TO FUEL MARKET GROWTH
• 10.4 HYBRID MODEL
  • 10.4.1 HIGH FLEXIBILITY OFFERED BY HYBRID MODEL TO SUPPORT MARKET GROWTH

11 CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN

• 11.1 INTRODUCTION
• 11.2 INTERVENTIONAL
  • 11.2.1 MAJOR ROLE OF INTERVENTIONAL TRIALS IN EVALUATING SAFETY AND EFFICACY OF NEW DRUGS AND DEVICES TO DRIVE MARKET
• 11.3 OBSERVATIONAL
  • 11.3.1 INCREASING RELIANCE ON OBSERVATIONAL STUDIES TO EVALUATE EFFICACY OF DRUGS IN REAL-WORLD SCENARIO TO SUPPORT MARKET GROWTH

12 CLINICAL TRIAL SERVICES MARKET, BY END USER

• 12.1 INTRODUCTION
• 12.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
  • 12.2.1 INCREASE IN R&D EXPENDITURE BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET
• 12.3 MEDICAL DEVICE COMPANIES
  • 12.3.1 RISING ACQUISITIONS AND EXPANSIONS OF SERVICE PORTFOLIOS BY MEDICAL DEVICE CRO SERVICE PROVIDERS TO DRIVE MARKET
• 12.4 ACADEMIC INSTITUTES
  • 12.4.1 RISING COLLABORATIONS BETWEEN CROS AND ACADEMIA TO DRIVE MARKET

13 CLINICAL TRIAL SERVICES MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 NORTH AMERICA
  • 13.2.1 US
    • 13.2.1.1 Presence of well-established CROs to drive market
  • 13.2.2 CANADA
    • 13.2.2.1 Favorable government-led initiatives and rising R&D investments to drive market
• 13.3 EUROPE
  • 13.3.1 GERMANY
    • 13.3.1.1 Growing R&D spending and favorable government policies to propel market
  • 13.3.2 UK
    • 13.3.2.1 Rising collaborations and improved policies to support market
  • 13.3.3 FRANCE
    • 13.3.3.1 Government-led support for effective drug research to drive market
  • 13.3.4 ITALY
    • 13.3.4.1 Government-led focus on improving clinical trial regulations to drive market
  • 13.3.5 SPAIN
    • 13.3.5.1 Rising R&D expenditure to boost market growth
  • 13.3.6 REST OF EUROPE
• 13.4 ASIA PACIFIC
  • 13.4.1 CHINA
    • 13.4.1.1 Low manufacturing cost and increased establishment of R&D centers to drive market
  • 13.4.2 INDIA
    • 13.4.2.1 Cost-efficient and innovation-driven approach to propel market
  • 13.4.3 JAPAN
    • 13.4.3.1 Decline in number of clinical trials to limit market
  • 13.4.4 AUSTRALIA
    • 13.4.4.1 Favorable tax incentives and cash rebates to pharmaceutical companies to support market
  • 13.4.5 SOUTH KOREA
    • 13.4.5.1 Favorable government initiatives for drug development to drive market
  • 13.4.6 REST OF ASIA PACIFIC
• 13.5 LATIN AMERICA
  • 13.5.1 BRAZIL
    • 13.5.1.1 Government-led support through improved policies in pharmaceutical R&D to drive market
  • 13.5.2 MEXICO
    • 13.5.2.1 Increasing investments in pharma R&D to drive market
  • 13.5.3 REST OF LATIN AMERICA
• 13.6 MIDDLE EAST
  • 13.6.1 GCC COUNTRIES
    • 13.6.1.1 Saudi Arabia
      • 13.6.1.1.1 Increase in collaborations to drive market
    • 13.6.1.2 UAE
      • 13.6.1.2.1 Growing clinical research activities to drive market
    • 13.6.1.3 Rest of GCC countries
  • 13.6.2 REST OF MIDDLE EAST
  • 13.6.3 AFRICA
    • 13.6.3.1 Expanding pharmaceutical industry to support market growth

14 COMPETITIVE LANDSCAPE

• 14.1 OVERVIEW
• 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
• 14.3 REVENUE ANALYSIS
• 14.4 MARKET SHARE ANALYSIS, 2024
• 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 14.5.1 STARS
  • 14.5.2 EMERGING LEADERS
  • 14.5.3 PERVASIVE PLAYERS
  • 14.5.4 PARTICIPANTS
  • 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 14.5.5.1 Company footprint
    • 14.5.5.2 Region footprint
    • 14.5.5.3 Service type footprint
    • 14.5.5.4 Phase footprint
• 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 14.6.1 PROGRESSIVE COMPANIES
  • 14.6.2 RESPONSIVE COMPANIES
  • 14.6.3 DYNAMIC COMPANIES
  • 14.6.4 STARTING BLOCKS
  • 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 14.6.5.1 Detailed list of key startups/SMEs
    • 14.6.5.2 Competitive benchmarking of startups/SMEs
• 14.7 COMPANY VALUATION AND FINANCIAL METRICS
• 14.8 BRAND/SERVICE COMPARISON
• 14.9 COMPETITIVE SCENARIO
  • 14.9.1 SERVICE LAUNCHES
  • 14.9.2 DEALS
  • 14.9.3 EXPANSIONS

15 COMPANY PROFILES

• 15.1 KEY PLAYERS
  • 15.1.1 IQVIA INC.
    • 15.1.1.1 Business overview
    • 15.1.1.2 Services offered
    • 15.1.1.3 Recent developments
      • 15.1.1.3.1 Service launches
      • 15.1.1.3.2 Deals
      • 15.1.1.3.3 Expansions
    • 15.1.1.4 MnM view
      • 15.1.1.4.1 Right to win
      • 15.1.1.4.2 Strategic choices
      • 15.1.1.4.3 Weaknesses and competitive threats
  • 15.1.2 ICON PLC
    • 15.1.2.1 Business overview
    • 15.1.2.2 Services offered
    • 15.1.2.3 Recent developments
      • 15.1.2.3.1 Service launches
      • 15.1.2.3.2 Deals
    • 15.1.2.4 MnM view
      • 15.1.2.4.1 Right to win
      • 15.1.2.4.2 Strategic choices
      • 15.1.2.4.3 Weaknesses and competitive threats
  • 15.1.3 THERMO FISHER SCIENTIFIC INC.
    • 15.1.3.1 Business overview
    • 15.1.3.2 Services offered
    • 15.1.3.3 Recent developments
      • 15.1.3.3.1 Service launches
      • 15.1.3.3.2 Deals
      • 15.1.3.3.3 Expansions
    • 15.1.3.4 MnM view
      • 15.1.3.4.1 Right to win
      • 15.1.3.4.2 Strategic choices
      • 15.1.3.4.3 Weaknesses and competitive threats
  • 15.1.4 FORTREA
    • 15.1.4.1 Business overview
    • 15.1.4.2 Services offered
    • 15.1.4.3 Recent developments
      • 15.1.4.3.1 Service launches
      • 15.1.4.3.2 Deals
      • 15.1.4.3.3 Expansions
    • 15.1.4.4 MnM view
      • 15.1.4.4.1 Right to win
      • 15.1.4.4.2 Strategic choices
      • 15.1.4.4.3 Weaknesses and competitive threats
  • 15.1.5 SYNEOS HEALTH
    • 15.1.5.1 Business overview
    • 15.1.5.2 Services offered
    • 15.1.5.3 Recent developments
      • 15.1.5.3.1 Service launches
      • 15.1.5.3.2 Deals
    • 15.1.5.4 MnM view
      • 15.1.5.4.1 Right to win
      • 15.1.5.4.2 Strategic choices
      • 15.1.5.4.3 Weaknesses and competitive threats
  • 15.1.6 LABORATORY CORPORATION OF AMERICA HOLDINGS
    • 15.1.6.1 Business overview
    • 15.1.6.2 Services offered
    • 15.1.6.3 Recent developments
      • 15.1.6.3.1 Service launches
      • 15.1.6.3.2 Deals
      • 15.1.6.3.3 Expansions
    • 15.1.6.4 MnM view
      • 15.1.6.4.1 Right to win
      • 15.1.6.4.2 Strategic choices
      • 15.1.6.4.3 Weaknesses and competitive threats
  • 15.1.7 MEDPACE
    • 15.1.7.1 Business overview
    • 15.1.7.2 Services offered
  • 15.1.8 WUXI APPTEC
    • 15.1.8.1 Business overview
    • 15.1.8.2 Services offered
    • 15.1.8.3 Recent developments
      • 15.1.8.3.1 Deals
  • 15.1.9 FRONTAGE LABS
    • 15.1.9.1 Business overview
    • 15.1.9.2 Services offered
    • 15.1.9.3 Recent developments
      • 15.1.9.3.1 Deals
      • 15.1.9.3.2 Expansions
  • 15.1.10 PHARMARON
    • 15.1.10.1 Business overview
    • 15.1.10.2 Services offered
  • 15.1.11 TIGERMED
    • 15.1.11.1 Business overview
    • 15.1.11.2 Services offered
    • 15.1.11.3 Recent developments
      • 15.1.11.3.1 Service approvals
      • 15.1.11.3.2 Deals
  • 15.1.12 SGS SOCIETE GENERALE DE SURVEILLANCE SA
    • 15.1.12.1 Business overview
    • 15.1.12.2 Services offered
  • 15.1.13 EUROFINS SCIENTIFIC
    • 15.1.13.1 Business overview
    • 15.1.13.2 Services offered
  • 15.1.14 LINICAL
    • 15.1.14.1 Business overview
    • 15.1.14.2 Services offered
    • 15.1.14.3 Recent developments
      • 15.1.14.3.1 Deals
      • 15.1.14.3.2 Expansions
  • 15.1.15 PAREXEL INTERNATIONAL CORPORATION
    • 15.1.15.1 Business overview
    • 15.1.15.2 Services offered
    • 15.1.15.3 Recent developments
      • 15.1.15.3.1 Service launches
      • 15.1.15.3.2 Deals
      • 15.1.15.3.3 Expansions
• 15.2 OTHER PLAYERS
  • 15.2.1 WORLDWIDE CLINICAL TRIALS
  • 15.2.2 PROPHARMA
  • 15.2.3 NOVOTECH
  • 15.2.4 PSI
  • 15.2.5 ALLUCENT
  • 15.2.6 PREMIER RESEARCH
  • 15.2.7 CAIDYA
  • 15.2.8 ERGOMED GROUP
  • 15.2.9 CLARIO
  • 15.2.10 PRECISION MEDICINE GROUP, LLC.
  • 15.2.11 ADVANCED CLINICAL
  • 15.2.12 EPS HOLDINGS, INC.
  • 15.2.13 GUIRES INC. (PEPGRA)
  • 15.2.14 KCR S.A.

16 APPENDIX

• 16.1 DISCUSSION GUIDE
• 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 16.3 CUSTOMIZATION OPTIONS
• 16.4 RELATED REPORTS
• 16.5 AUTHOR DETAILS